THE UNIVERSITY OF BRITISH COLUMBIA
The Respiratory Evaluation Sciences Program (RESP) is a comprehensive epidemiology, health outcomes, and health economics program focused on chronic respiratory diseases (namely asthma and chronic obstructive pulmonary disease [COPD]).
Our group has diverse expertise in using clinical data, real-world 'big' data, and computer simulations (disease modeling) techniques to evaluate the real-world effectiveness of health technologies and their 'value for money' potential. Our research has continuously been supported through multiple grants from CIHR and other agencies.
See more of our research by following categories:
Modifiable factors associated with inappropriate use of asthma relievers
Identifying factors associated with inappropriate or excessive use of short-acting beta agonists (SABA) in asthma can help efforts towards safer use of such medications. We used British Columbian (BC)’s administrative health data to create a retrospective...
Characterizing undiagnosed chronic obstructive pulmonary disease: a systematic review and meta-analysis
A significant proportion of patients with chronic obstructive pulmonary disease (COPD) remain undiagnosed. Characterizing these patients can increase our understanding of the 'hidden' burden of COPD and the effectiveness of case detection interventions.
Multiple- treatment comparison versus pairwise meta-analysis as the evidence synthesis framework economic evaluations
Our case study showed that the choice of pairwise or multiple treatment comparison (MTC) can have significant effects on value of information outcomes. The incorporation of indirect evidence into the evidence-base likely adds valuable precision. As a resu...
RESP is hosted within UBC Faculty of Pharmaceutical Sciences. Our partners include UBC Division of Respiratory Medicine, and Centre for Clinical Epidemiology and Evaluation.
Our research has been funded by peer-reviewed grants from multiple institutions, including: